Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease.
Epithelioid Hemangioendothelioma (EH) is a rare soft-tissue tumor which may present as an isolated tumor or can spread to affect internal organs. The course of EH varies, based on the tissue of origin. This case report describes a young woman who developed cutaneous EH with concurrent intracranial disease during pregnancy. After resection, the lesions returned. Even after several courses of chemotherapy and radiotherapy, the patient developed multifocal disease including pulmonary, skeletal, and liver disease. She now exhibits stable disease after approximately 6 years of therapy with lenalidomide.
Sumrall
Ashley
A
Department of Oncology, University of Mississippi Medical Center, Jackson, MS, USA. ashleysumrall@bellsouth.net
Fredericks
Ruth
R
Berthold
Anne
A
Shumaker
Grace
G
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D018323:Hemangioendothelioma, Epithelioid / Q000188:drug therapy*; D006801:Humans; D000077269:Lenalidomide; D008279:Magnetic Resonance Imaging; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide